Spike Trimer (S1+S2) (B.1.351, Beta Variant) (SARS-CoV-2): ACE2 Inhibitor Screening Colorimetric Assay Kit
The SARS-CoV-2 Spike Trimer (S1+S2) (B.1.351 Variant):ACE2 Inhibitor Screening Colorimetric Assay Kit is designed for screening and profiling inhibitors or neutralizing antibodies of this interaction. The key to this kit is that the SARS-CoV-2 Spike Trimer (S1+S2) (B.1.351 Variant) protein provides a more biologically relevant model than monomeric Spike RBD protein for the investigation of SARS-CoV-2/host cell interaction. Only a few simple steps on a microtiter plate are required for the assay. First, SARS-CoV-2 Spike Trimer (S1+S2) (B.1.351 Variant) is coated on a 96-well plate overnight. Next, the proteins are blocked and pre-incubated with the inhibitor or neutralizing antibody. Upon subsequent incubation with Biotin-ACE2, the plate is treated with Streptavidin-HRP followed by addition of a colorimetric HRP substrate to produce color, which then can be quenched and measured using a UV/Vis microplate reader.
Assay Principle
PBS (Phosphate buffered saline)
1N HCl (aqueous)
Rotating or rocker platform
UV/Vis spectrophotometer microplate reader capable of reading absorbance at 450 nm*
| Catalog | Name | Amount | Storage |
| 510333 | Spike Trimer (S1+S2) (B.1.351 Variant), His-Tag (SARS-CoV-2) | 5 µg | -80°C |
| 100665 | ACE2, His-Avi-Tag, Biotin labeled | 5 µg | -80°C |
| 79311 | 3x Immuno Buffer 1 | 50 ml | -20°C |
| 79728 | Blocking Buffer 2 | 50 ml | +4°C |
| 79742 | Streptavidin-HRP | 5 µl | +4°C |
| Colorimetric HRP substrate | 10 ml | +4°C | |
| 79964 | Transparent 96-well microplate | 1 | Room Temp |
The COVID-19 pandemic is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The Spike glycoprotein is expressed on the surface of the virus as a trimer. Each Spike protein consists of two subunits, S1 and S2, and the S1 subunit has a receptor binding domain (RBD) which recognizes and attaches to the ACE2 receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. The SARS-CoV-2 Variant B.1.351 originally discovered in South Africa and contains the nine known mutations, L18F, D80A, D215G, R246I, K417N, E484K, N501Y, D614G, A701V. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer some protection against the viral infection. The SARS-CoV-2 Spike Trimer (S1+S2) (B.1.351 Variant):ACE2 Inhibitor Screening Colorimetric Assay Kit includes the South African Variant Spike protein in its native trimeric conformation to provide a more physiologically relevant screen for inhibitors of the Spike S1:ACE2 interaction.
Powered by Bioz
San Diego, CA 92121
858-202-1401
Products are for Research Use Only
COMPANY
Copyright © 2024
BPS Bioscience, Inc.
All rights reserved.
Diagrams on this website are created with BioRender.com.